Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic White Population in the United States With Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the number of non-Hispanic white individuals in the United States avoiding legal blindness and visual impairment from neovascular age-related macular degeneration (AMD) with ranibizumab availability. METHODS: Modeling of visual acuity outcomes from phase 3 ranibizumab trials to incidence rates of neovascular AMD from population-based studies. RESULTS: If no treatment were given, of the 103 582 individuals developing neovascular AMD for which ranibizumab would be indicated and available, 16 268 would become legally blind in 2 years. Monthly ranibizumab would reduce the incidence of legal blindness in 2 years by 72% (95% confidence interval [CI], 70% to 74%) to 4484 individuals. If no treatment were given, 34 702 would become visually impaired. Monthly ranibizumab would reduce the incidence of visual impairment in 2 years by 37% (95% CI, 35% to 39%) to 21 919 cases. CONCLUSIONS: Ranibizumab should have a substantial effect on reducing the magnitude of legal blindness and visual impairment within 2 years after diagnosis of neovascular AMD among non-Hispanic white individuals in the United States. Although racial subgroups other than non-Hispanic whites were not considered (because there is limited information in the literature regarding incidence rates of choroidal neovascularization in other populations) and although these results assume access to and application of monthly ranibizumab for 2 years, the number of individuals developing legal blindness or vision impairment from neovascular AMD should be reduced dramatically if monthly ranibizumab is applied when indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Income, Poverty, and Health Insurance Coverage In The United States: 2006: (668082007-001)
DeNavas-Walt, C., Proctor, B. D., & Smith, J. (2007) · PsycEXTRA Dataset · doi:10.1037/e668082007-001 · Cited by 1,636
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS Report No. 11
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.11.1621 · Cited by 374
Self-citationKaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361 · cited 2×
“Legal blindnessa No treatment for CNV under center of macula 16 268 (16) 12 052 to 21 145 (12-20) .”
Background
Cited by
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Deep learning in ophthalmology: The technical and clinical considerations
Ting, D. S. W., Peng, L., Varadarajan, A. V., Keane, P. A., Burlina, P. M., Chiang, M. F., Schmetterer, L., Pasquale, L. R., Bressler, N. M., Webster, D. R., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.04.003 · Cited by 534
Self-citationAge-related macular degeneration
Guymer, R. H., & Campbell, T. G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02609-5 · Cited by 502
Mechanisms of age‐related macular degeneration and therapeutic opportunities
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014) · The Journal of Pathology · doi:10.1002/path.4266 · Cited by 382
“For example, in a study evaluating 103,582 individuals developing NVAMD, about 16% would become legally blind in 2 years without treatment [16].”
BackgroundIncidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Bloch, S. B., Larsen, M., & Munch, I. C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.10.016 · Cited by 377
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Updates on the Epidemiology of Age-Related Macular Degeneration
(2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017251 · Cited by 266
Time Trends in the Incidence and Causes of Blindness in Israel
Skaat, A., Chetrit, A., Belkin, M., Kinori, M., & Kalter-Leibovici, O. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.035 · Cited by 115
Khanani, A. M., Skelly, A., Bezlyak, V., Griner, R., Torres, L. R., & Sagkriotis, A. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2019.09.009 · Cited by 96
Wu, J., Cho, E., Giovannucci, E. L., Rosner, B. A., Sastry, S. M., Willett, W. C., & Schaumberg, D. A. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.12.033 · Cited by 74
“Although the advanced stages of AMD are often debilitating, some forms of advanced AMD can now be successfully managed with intravitreal injection of antievascular endothelial growth factor (VEGF) agents, allowing patients to maintain or even restore vision for variable periods of time.(2,3) However, although usually…”
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Parmeggiani, F., Gallenga, C. E., Costagliola, C., Semeraro, F., Romano, M. R., Dell’Omo, R., Russo, A., De Nadai, K., Gemmati, D., D’Angelo, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38919-7 · Cited by 7
Metadata
- Authors
- Bressler, N. M., Doan, Q. V., Varma, R., Lee, P. P., Suñer, I. J., Dolan, C., Danese, M. D., Yu, E., Tran, I., & Colman, S.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2011-06-13
- Volume
- 129
- Issue
- 6
- Pages
- 709-17
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2018888303
- Cited by
- 118
- References
- 9
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.